Chronic inflammation and altered mitochondrial metabolism contribute to abnormal cellular proliferation, tissue remodeling, fibrosis, and organ damage and are associated with many diseases1-3
The Keap1/Nrf2 pathway plays a key role in the resolution of inflammation by normalizing mitochondrial function, restoring redox balance, and suppressing cytokine production4-6
Reata is developing a series of small molecules that facilitate the resolution of inflammation by binding to Keap1 and increasing Nrf2 activity. Our two lead Nrf2 activators—bardoxolone methyl and omaveloxolone—exhibit broad anti-inflammatory, antifibrotic, and promitochondrial activity in vitro and in preclinical disease models
Bardoxolone methyl and omaveloxolone are being evaluated in phase 2 and/or phase 3 clinical trials for the treatment of several chronic diseases in which mitochondrial dysfunction and inflammation are implicated. Bardoxolone methyl is being evaluated in several forms of chronic kidney disease including Alport syndrome, autosomal dominant polycystic kidney disease, IgA nephropathy, type 1 diabetic CKD, and focal segmental glomerulosclerosis as well as a severe from of pulmonary arterial hypertension associated with connective tissue disease. Omaveloxolone is being evaluated in a severe neurologic disease called Friedreich’s ataxia.
Gilroy D, De Maeyer R. New insights into the resolution of inflammation. Semin Immunol. 2015;27(3):161-168.
Mills EL, O’Neill LA. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol. 2016;46(1):13-21.
Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-κB: a blossoming of relevance to human pathobiology. Cell. 2017;168:37-57.
Rimessi A, Previati M, Nigro F, Wieckowski MR, Pinton P. Mitochondrial reactive oxygen species and inflammation: Molecular mechanisms, diseases, and promising therapies. Int J Biochem Cell Biol. 2016;81(pt B):281-293.
Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol. 2015;7(5):pii:a016303.
Koenderman L, Buurman W, Daha MR. The innate immune response. Immunol Lett. 2014;163:95-102.
Freigang S. The regulation of inflammation by oxidized phospholipids. Eur J Immunol. 2016;46:1818-1825.
Paupe V, Dassa EP, Goncalves S, et al. Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia. PLoS One. 2009;4(1):e4253.
Sykiotis GP, Bohmann D. Stress-activated cap’n’collar transcription factors in aging and human disease. Sci Signal. 2010;3(112):re3.
Chiurchiù V, Leuti A, Maccarrone M. Bioactive lipids and chronic inflammation: managing the fire within. Front Immunol. 2018;9:38.
Probst BL, Trevino I, McCauley L, et al. RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One. 2015;10(4):e0122942.
Yates MS, Tauchi M, Katsuoka F, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther. 2007;6(1):154-162.
Ahmed SM, Luo L, Namani A, Wang XJ, Tang X. Nrf2 signaling pathway: pivotal roles in inflammation. Biochim Biophys Acta Mol Basis Dis. 2017;1863(2):585-597.
Holmström KM, Kostov RV, Dinkova-Kostova AT. The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol. 2016;1:80-91.